University of Miami Clinical Psychopharmacology Beyond Conventional Wisdom 2026

1. Overview
The presentation places a strong emphasis on diagnostic accuracy and the application of research-driven clinical practices, prioritizing efficacy and safety as demonstrated in clinical trials over speculative biological mechanisms. In-depth analysis and treatment strategies will be provided for schizophrenia, bipolar disorder, depression, and anxiety disorders, with additional focus on mixed states, bipolar depression, and the nuanced role of psychopharmacology in optimizing treatment outcomes.
The seminar will incorporate the latest research findings, including recent advancements in clinical psychopharmacology, to ensure participants are equipped with up-to-date knowledge and skills. Special attention will be given to the application of these strategies in diverse patient populations, including children, the elderly, and those with comorbid medical conditions, to promote holistic and effective patient care.
Course Date: February 16-20, 2026
2. Learning Objectives
Upon completion of this activity, participants will be able to:

Describe the historical background on the major themes to be covered during the course.
Examine the biological mechanisms of major psychotropic drug classes.
Grasp the basic neuroanatomy relevant to clinical psychopharmacology.
Recognize and apply key clinical trials of drug classes for various diagnoses.
Examine the validity of DSM diagnoses and learn how to use non-DSM approaches to diagnosis and drug treatment.
Discuss practices with antipsychotics, mood stabilizers, and antidepressants.
Explain the risks and side effects of major drug classes.
Employ medications with an understanding of pharmacokinetic interactions.
Identify factors in medication use for those with comorbid medical conditions.

3. Target Audience

Best for psychiatrists and mental health clinicians who want updates on psychopharmacology, drug safety, and mood disorder management.

4. Topics

01 Bipolar Depression and Mixed States – Why Antidepressants Fail and Dopamine Blockers Work

02 Mood Stabilizers in Bipolar Disorder – Limitations of Anticonvulsants vs Lithium

03 How Mood Temperaments Drive Misdiagnosis in Psychiatry

04 Treating Mood Temperaments to Improve Mental Health Outcomes

05 Antipsychotic Safety – Neurotoxicity, Akathisia, and Tardive Dyskinesia Risks

06 Lithium in Mood Disorders – Is It the Safest Mood Stabilizer

07 Lithium Safety and Renal Effects – Interpreting eGFR and True Kidney Risk

08 Antipsychotics in Schizophrenia – Short-Term Symptom Control vs Long-Term Outcomes

09 Antipsychotic-Induced Akathisia and EPS – Clinical Risks and Management

10 Antipsychotics and Metabolic Risk – Insulin Resistance, Weight Gain, & More

11 Bipolar Mania Management With Antipsychotics – Acute Efficacy vs Maintenance Limitations

12 ADHD – Clinical Efficacy and Safety of Amphetamine-Based Therapies

13 Antidepressant Safety Risks – Suicidality, Cardiovascular Effects, and Withdrawal Syndromes

14 MDD Maintenance Treatment – Do Antidepressants Sustain Remission

15 Acute Treatment of Major Depressive Disorder – Interpreting Effect Size, Placebo Response, and Clinical Meaningfulness

16 Do Antidepressants Work in Bipolar Depression or Worsen Outcomes

17 Basic Concepts of Psychopharmacology for the Clinician

18 Neurobiology in Psychopharmacology – Why Mechanisms Matter Less Than Clinical Outcomes

19 Antipsychotic Psychopharmacology – Receptor Affinity, Dosing, and Adverse Effects

20 Mood Stabilizer Neurobiology – Lithium and Antiepileptics Mechanisms

21 Psychopharmacology of Monoamine Agonists From Chemical Structure to Clinical Effect

22 Benzodiazepines & Alternatives for Sleep and Anxiety Disorders – Pharmacology & Adverse Effects